ClinicalTrials.gg
RecruitingNCT05933629Updated Jul 16, 2026

Community-based Implementation of Online EmReg

An interventional study of Online EmReg and Consultation Sessions in Traumatic Brain Injury and Emotion Regulation, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai — 2 open to participants now, 2 under way, none of them phase 3. Brain Injuries, Traumatic · Icahn School of Medicine at Mount Sinai.

Planned enrollment
8th of 11
50 · median 77
Started
2023
the only one that year
No phase
9 of 11
2 open now
Registered
9th of 11
by date

Among the 11 studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai, this one is the 8th largest by planned enrollment, is the only one that started in 2023, is one of 9 with no phase, and was the 9th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

2 of the 11 studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai, or all of them as a file.
02

Study summary

This is a hybrid type III implementation-effectiveness trial; this study design blends elements of implementation and clinical effectiveness research, with the primary aim of determining the utility of an implementation strategy and a secondary aim of assessing clinical outcomes associated with the implementation trial. Consistent with best practices for this type of design, the study team will conduct a randomized test of the effect of implementation strategy on effective delivery of the Online EmReg intervention in clinical practice. Specifically, the study team will compare Standard Training (a 3-hour on-demand training workshop) to Extended Training, (a 3-hour on-demand training workshop with 3 months of bi-weekly consultation). The research team's primary aim is to determine the optimal strategy to train clinicians in effectively delivering Online EmReg, and secondary aim is to assess patient improvement per clinician-administered DERS. Outcome measures will be assessed via self-report surveys, performance evaluations (via role-plays), and tracked clinician participation and fidelity. Study participation is expected to last up to 18 months.

03

Conditions studied

  • Traumatic Brain Injury
  • Emotion Regulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Licensed psychologist, social worker, or mental health counselor.
  • Training and experience in CBT, the framework for EmReg.
  • Experience working with people with TBI.
  • Experience providing group treatment.
  • A computer and internet to conduct group treatment via telehealth.
  • Actively treating ≥3 patients with TBI who are appropriate for EmReg (have emotion regulation difficulties based on clinician assessment).
  • Amenable to study tasks (e.g., completion of training, consultation, performance based role-play, data collection).
  • Not previously trained in EmReg.
  • Proficient in English.

Exclusion criteria

Exclusion Criteria:

  • Not willing to conduct group treatment via telehealth.
  • Non-English speaking.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Standard Training

    Participants assigned to this arm will complete a 3-hour training workshop on the intervention. After completing the training, participants will be asked to implement the intervention into their routine clinical practice.

    Behavioral: Online EmReg

  • Experimental
    Extended Training

    Participants assigned to this arm will complete the same 3-hour training workshop on the intervention as Arm #1. After completing the training, participants will also be asked to implement the intervention into their routine clinical practice. However, participants in this group will be asked to attend bi-weekly consultation sessions with members of the study team for 3 months following training.

    Behavioral: Online EmReg · Behavioral: Consultation Sessions

Interventions

  • BehavioralOnline EmReg

    A Web-based group intervention to improve emotion regulation in individuals with traumatic brain injury (TBI). Online EmReg is a 3-hour on-demand training workshop

  • BehavioralConsultation Sessions

    3 months of bi-weekly consultation sessions

06

What researchers measure

Primary outcomes

  1. Provider Self-Efficacy Scale Score

    A 7-item Likert Scale (not at all confident (1) to fully confident (7)) adapted for use with EmReg to assess provider confidence in delivering core components of the Online EmReg intervention. Total scores range from 26 to 182. Higher values indicate a higher level of self-efficacy. Used in the literature to reliably predict implementation of evidence-based interventions.

    Time frame: Up to 18 months

  2. Performance Evaluation (via Role Plays)

    Assessed using a structured role play of EmReg groups in a simulated clinical setting. These role plays will be recorded and rated by a blinded evaluator. The evaluator will indicate the degrees to which the session goals were accomplished using a 15-item checklist. Each item will be rated a 0 (not introduced or covered), 1 (attempted/partially achieved), 2 (fully covered/achieved), or N/A (not applicable/relevant to session #). Participants can receive a total score of 0 to 30 on their performance-based role play. Higher values indicate higher achievement.

    Time frame: Post-3 hour EmReg training workshop

Secondary outcomes

  1. Training Satisfaction Rating Scale

    Satisfaction with training will be assessed using the Training Satisfaction Rating Scale, a 12-item, 5-point Likert scale (higher scores = higher satisfaction). Total scores range from 12 to 60. Training engagement and consultation engagement (extended group only) will be tracked by study team.

    Time frame: Up to 18 months

  2. Acceptability of Intervention Measure (AIM)

    Provider's satisfaction with the intervention will be assessed using the Acceptability of Intervention Measure (AIM), a 4-item, 5-point Likert scale. Total scores can range from 4 to 20 with higher scores indicating greater acceptability.

    Time frame: Up to 18 months

  3. Feasibility of Intervention Measure (FIM) Scale

    Feasibility of the intervention will be assessed using the Feasibility of Intervention Measure (FIM), a 4-item, 5-point Likert scale. Total scores can range from 4 to 20 with higher scores indicating greater feasibility.

    Time frame: Up to 18 months

  4. Intervention Appropriateness Measure (IAM) Scale

    Appropriateness of the intervention will be assessed using the Intervention Appropriateness Measure (IAM), a 4-item, 5-point Likert scale. Total scores can range from 4 to 20 with higher scores indicating greater intervention appropriateness.

    Time frame: Up to 18 months

  5. Number of EmReg groups scheduled and completed

    The number of EmReg groups scheduled and completed by the clinician participants

    Time frame: Up to 18 months

  6. Time between initial uptake and completion

    The time between completion of training and initial uptake will be tracked.

    Time frame: Up to 18 months

  7. Skills Acquisition Quiz for Providers (SAQ-P)

    Clinician participants will be given a 25-item multiple-choice test of knowledge of Online EmReg training content. Correct answers are coded as 1 and incorrect answers are coded as 0. Scores range from 0-25 with higher scores indicating greater knowledge of the intervention.

    Time frame: Up to 18 months

  8. Number of participants who receive treatment

    Clinician participants will be asked to track the number of patients who receive treatment out of those who appear eligible.

    Time frame: Up to 18 months

  9. Difficulties in Emotion Regulation Scale (DERS)

    A 36-item questionnaire assessing capacity for emotion regulation. Each item is scored on a 5-point scale. Total scores range from 80 to 136. Out of the 36 items, 11 are reverse scored. Higher scores suggest greater problems with emotion regulation.

    Time frame: Up to 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Currently, there is no plan to share individual participant data. Results will be published by the investigators in academic journals.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Aug 2027, 49 months after the start.

Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 49 months is above that.

Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 6, 2023
StartActual
Jul 18, 2023
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05933629
Responsible party
Maria Kajankova (Assistant Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Jul 6, 2023
Start date
Jul 18, 2023
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jul 16, 2026

Study contacts

Emily Blunt, BA
Contact
emily.blunt@mountsinai.org
212-241-0818
Annell Ovalles, MPH
Contact
annell.ovalles@mountsinai.org
212-241-4706
Maria Kajankova, PhD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion